Research Article

Autoantibodies to NR2A Peptide of the Glutamate/NMDA Receptor in Patients with Seizure Disorders in Neuropsychiatric Systemic Lupus Erythematosus

Table 3

Comparison of clinical characteristics between patients with seizure and without seizure in NPSLE group.

NPSLETest value value
With seizure ()Without seizure ()

Number of males/females2/152/170.0140.906
Age (years), median (range)25 (18 to 51)24 (19 to 60)−0.6510.519
SLEDAI, median (range)22 (16 to 30)14 (8 to 19)6.571
Consciousness disorders, 12 (71%)020.118
ANA (U/mL), median (range)175.0 (106.3 to 657.3)175.0 (45.8 to 696.9)0.4990.621
Anti-dsDNA (U/mL), median (range)233.0 (69.7 to 671.3)207.8 (25.6 to 717.5)−0.0680.946
Anti-ribosomal P antibodies, 6 (35%)8 (42%)0.1750.676
SSA, 11 (65%)9 (47%)1.0920.296
SSB, 3 (18%)3 (16%)0.0220.881
C3 (g/L), median (range)0.32 (0.13 to 1.08)0.38 (0.26 to 0.83)−0.9490.349
C4 (g/L), median (range)0.05 (0.01 to 0.32)0.09 (0.05 to 0.33)−0.6910.494
Number with/without treatment13/414/5
Users of prednisone (%)11 (65%)8 (42%)1.8390.175
Dose (mg/day), median (range)7.5 (2.5 to 50)10 (2.5 to 100)
Users of hydroxychloroquine (%)9 (53%)8 (42%)0.4230.516
Dose (mg/day), median (range)400 (150 to 400)400 (200 to 400)